Skip to main content
. 2013 Feb 21;33(2):125–129. doi: 10.3343/alm.2013.33.2.125

Fig. 2.

Fig. 2

Immunophenotypic findings of bone marrow aspirate at relapse (A) and on day 49 post-HSCT (B). (A) Leukemic myeloblasts with CD45 intermediate expression show the positivity of immature myeloid markers (CD34 and CD117) at relapse. (B) Atypical mast cells with CD45 intermediate to bright expression show the positivity of neoplastic mast cell markers (CD117 and CD25) on day 49 post-HSCT.

Abbreviation: SSC, side scatter.